Bank Julius Baer & Co
TRIL

Bank Julius Baer & Co’s Trillium Therapeutics Inc. TRIL Stock Holding History

Bank Julius Baer & Co’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-450
Closed -$6K – 871
2020
Q3 		$6K Buy
+450
New +$4.49K ﹤0.01% 701

Other funds holding TRIL

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Bank Julius Baer & Co's TRIL Position: Q4 2020 in Review

Bank Julius Baer & Co sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2020, closing a stake of 450 shares — an estimated $6K sold.

Bank Julius Baer & Co first reported a position in TRIL in Q3 2020 and held it in 1 quarter. The position peaked at $6K in Q3 2020. 131 funds tracked by Wall St. Rank hold TRIL as of Q4 2020.

  • Bank Julius Baer & Co reported no remaining Trillium Therapeutics Inc. position as of Q4 2020 after selling out during the quarter.
  • Bank Julius Baer & Co sold 450 Trillium Therapeutics Inc. shares in Q4 2020, an estimated $6K.
  • Bank Julius Baer & Co first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 1 quarter.
  • Bank Julius Baer & Co's Trillium Therapeutics Inc. position peaked at $6K in Q3 2020.
  • 131 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2020.

Based on Bank Julius Baer & Co's 13F filing for Q4 2020, filed 12 Feb 2021.